Featured Research

from universities, journals, and other organizations

Pneumococcal Vaccine Associated With 50 Percent Lower Risk Of Heart Attacks

Date:
October 8, 2008
Source:
Canadian Medical Association Journal
Summary:
Pneumococcal (pneumonia) vaccination was associated with a 50 percent lower risk of heart attacks two years after vaccination, suggests a large hospital-based case-control study.

Pneumococcal (pneumonia) vaccination was associated with a 50% lower risk of heart attacks 2 years after vaccination, suggests a large hospital-based case-control study published in CMAJ.

In a population of patients at high risk of heart attack, the study compared the rates of pneumococcal vaccine between patients having a heart attack and patients without such an event.

“After a number of confounding and modifying variables were taken into account, the odds of having received a vaccination against S. pneumonia in the group who had experienced myocardial infarction was about half that in the control group,” write Dr. Danielle Pilon and coauthors from the University of Sherbrooke and McMaster University. “Moreover, this association appeared stronger and the benefit appeared to increase with time since exposure to the vaccine.”

In a related commentary, Dr. Mohammad Madjid from the Texas Heart Institute hypothesizes that the pneumonia vaccine protects against heart attacks because it prevents pneumonia which has been shown to trigger heart attacks. Other studies suggest that respiratory (especially influenza) and urinary tract infections are associated with heart attacks. He suggests that physicians should focus on increasing vaccination rates against pneumonia and influenza in high risk patients as rates in the US and other countries are well below target goals.


Story Source:

The above story is based on materials provided by Canadian Medical Association Journal. Note: Materials may be edited for content and length.


Journal References:

  1. Franηois Lamontagne, Marie-Pierre Garant, Jean-Christophe Carvalho, Luc Lanthier, Marek Smieja, and Danielle Pilon. Pneumococcal vaccination and risk of myocardial infarction. CMAJ, 2008; 179: 773-777 DOI: 10.1503/cmaj.070221
  2. Mohammad Madjid. Acute infections, vaccination and prevention of cardiovascular disease. CMAJ, 2008; 179: 749-750 DOI: 10.1503/cmaj.081302

Cite This Page:

Canadian Medical Association Journal. "Pneumococcal Vaccine Associated With 50 Percent Lower Risk Of Heart Attacks." ScienceDaily. ScienceDaily, 8 October 2008. <www.sciencedaily.com/releases/2008/10/081006180506.htm>.
Canadian Medical Association Journal. (2008, October 8). Pneumococcal Vaccine Associated With 50 Percent Lower Risk Of Heart Attacks. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/10/081006180506.htm
Canadian Medical Association Journal. "Pneumococcal Vaccine Associated With 50 Percent Lower Risk Of Heart Attacks." ScienceDaily. www.sciencedaily.com/releases/2008/10/081006180506.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins